期刊
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
卷 76, 期 6, 页码 1037-1043出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/gerona/glaa222
关键词
Dementia risk factors; Drug Burden Index; Memory complaints
The study found that anticholinergic/sedative drug burden is associated with subjective cognitive decline in older adults, especially among individuals aged 65 and older. The interaction between age and drug burden is important when predicting AD risk.
Background: Anticholinergic/sedative drug use, measured by the Drug Burden Index (DBI), has been linked to cognitive impairment in older adults. Subjective cognitive decline (SCD) may be among the first symptoms patients with Alzheimer's disease (AD) experience. We examined whether DBI values are associated with SCD in older adults at risk of AD. We hypothesized that increased DBI would be associated with greater SCD at older ages. Method: Two-hundred-six community-dwelling, English-speaking adults (age = 65 9 years) at risk of AD (42% apolipoprotein epsilon 4 carriers; 78% with AD family history) were administered a single question to ascertain SCD: Do you feel like your memory is becoming worse? Response options were No; Yes, but this does not worry me; and Yes, this worries me. DBI values were derived from self-reported medication regimens using older adult dosing recommendations. Adjusting for relevant covariates (comorbidities and polypharmacy), we examined independent effects of age and DBI on SCD, as well as the moderating effect of age on the DBI-SCD association at mean 1 SD of age. Results: Both SCD and anticholinergic/sedative drug burden were prevalent. Greater drug burden was predictive of SCD severity, but age alone was not. A significant DBI*Age interaction emerged with greater drug burden corresponding to more severe SCD among individuals age 65 and older. Conclusion: Anticholinergic/sedative drug exposure was associated with greater SCD in adults 65 and older at risk for AD. Longitudinal research is needed to understand if this relationship is a pre-clinical marker of neurodegenerative disease and predictive of future cognitive decline.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据